IsoDOT Detects Differential RNA-Isoform Expression/Usage With Respect to a Categorical or Continuous Covariate With High Sensitivity and Specificity by Sun, Wei et al.
IsoDOT Detects Differential RNA-isoform Expression/Usage with 
respect to a Categorical or Continuous Covariate with High 
Sensitivity and Specificity
Wei Sun [Associate Professor],
Department of Biostatistics, Department of Genetics, UNC Chapel Hill, NC 27599
Yufeng Liu [Professor],
Department of Statistics and Operations Research, Department of Genetics, Department and 
Biostatistics, UNC Chapel Hill
James J. Crowley [Research Assistant Professor],
Department of Genetics, UNC Chapel Hill
Ting-Hued Chen [postdoc fellow],
National Cancer Institute
Hua Zhou [Assistant Professor],
Department of Statistics, NC State University
Haitao Chu [Associate Professor],
Department of Biostatistics, University of Minnesota
Shunping Huang [Research Statistician Developer],
SAS Institute Inc
Pei-Fen Kuan [Assistant Professor],
Department of Applied Mathematics and Statistics, Stony Brook University
Yuan Li [graduate student],
Department of Statistics, NC State University
Darla R. Miller [Project Manager of the Collaborative Cross],
Department of Genetics, Lineberger Comprehensive Cancer Center, UNC Chapel Hill
Ginger D. Shaw [Research Specialist],
Department of Genetics, Lineberger Comprehensive Cancer Center, UNC Chapel Hill
Yichao Wu [Associate Professor],
Department of Statistics, NC State University
Vasyl Zhabotynsky, DrPH [student],
Department of Biostatistics, UNC Chapel Hill
Leonard McMillan [Associate Professor],
Department of Computer Science, UNC Chapel Hill
Fei Zou [Professor],
Department of Biostatistics, UNC Chapel Hill
HHS Public Access
Author manuscript
J Am Stat Assoc. Author manuscript; available in PMC 2015 November 27.
Published in final edited form as:













Patrick F. Sullivan [Distinguished Professor], and
Department of Genetics, Department of Psychiatry, Department of Epidemiology, UNC Chapel 
Hill
Fernando Pardo-Manuel de Villena [Professor, Associate Chair for Research]
Department of Genetics, UNC Chapel Hill
Wei Sun: weisun@email.unc.edu
Abstract
We have developed a statistical method named IsoDOT to assess differential isoform expression 
(DIE) and differential isoform usage (DIU) using RNA-seq data. Here isoform usage refers to 
relative isoform expression given the total expression of the corresponding gene. IsoDOT 
performs two tasks that cannot be accomplished by existing methods: to test DIE/DIU with respect 
to a continuous covariate, and to test DIE/DIU for one case versus one control. The latter task is 
not an uncommon situation in practice, e.g., comparing the paternal and maternal alleles of one 
individual or comparing tumor and normal samples of one cancer patient. Simulation studies 
demonstrate the high sensitivity and specificity of IsoDOT. We apply IsoDOT to study the effects 
of haloperidol treatment on the mouse transcriptome and identify a group of genes whose isoform 
usages respond to haloperidol treatment.
Keywords
RNA-seq; isoform; penalized regression; differential isoform expression; differential isoform 
usage
In the genomes of higher eukaryotes, the DNA sequence of a gene often includes multiple 
exons that are separated by introns. A multi-exon gene may encode several RNA isoforms, 
each with a unique subset of exons. Recent studies have shown that more than 90% of 
human genes have multiple RNA isoforms which may be differentially expressed across 
tissues or developmental stages [Wang et al., 2008, Pan et al., 2008], and about 75% of 
human genes produce multiple RNA isoforms within a given cell type [Djebali et al., 2012]. 
Therefore, study of RNA-isoform expression and its regulation is of great importance to 
understand the functional complexity of a living organism, the evolutionary changes in 
transcriptome [Barbosa-Morais et al., 2012], and the genomic basis of human diseases 
[Wang and Cooper, 2007].
Gene expression has traditionally been measured by microarrays or exon arrays, most of 
which provide just a handful of probes per gene and poor resolution to distinguish multiple 
isoforms. [Purdom et al., 2008, Richard et al., 2010]. RNA sequencing (RNA-seq), on the 
other hand, provides much better data for this purpose [Wang et al., 2009]. In RNA-seq, 
fragments of RNA molecules (typically 200-500 bps long) are reverse transcribed and 
amplified, followed by sequencing of one or both ends (single vs paired-end). Each 
sequence is referred to as a read, which could be 30 - 150 bps or even longer. Reads are then 
mapped to a reference genome and the number of fragments overlapping each gene is 
counted. The expression of the j-th gene in the i-th sample is measured by a normalized 
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fragment count after adjusting for read-depth of the i-th sample and the length of the j-th 
gene [Mortazavi et al., 2008].
The primary challenge with studying RNA isoforms is that we cannot directly observe the 
expression of each RNA isoform. More specifically, an RNA-seq fragment may be 
compatible with more than one RNA isoform, and thus we cannot unambiguously assign it 
to an RNA isoform. Several methods have been developed to address this challenge [Jiang 
and Wong, 2009, Salzman et al., 2011, Richard et al., 2010, Xing et al., 2006, Trapnell et al., 
2010, Roberts et al., 2011, Li et al., 2010, Katz et al., 2010, Pachter, 2011, Chen, 2012]. 
Moreover, the annotation of RNA isoforms may not be complete or accurate and thus one 
may need to reconstruct transcriptome annotation using RNA-seq data [Denoeud et al., 
2008]. Simultaneous transcriptome reconstruction and isoform abundance estimation can be 
achieved using different approaches, including penalized regression methods [Xia et al., 
2011, Bohnert and Rätsch, 2010, Li et al., 2011b,a], where each possible isoform is treated 
as a covariate in a regression problem. Interested readers are referred to Ala-mancos et al. 
[2014] for a comprehensive list of relevant statistical/computational methods.
Differential isoform expression (DIE) and differential isoform usage (DIU) are related but 
distinct concepts. DIE assesses the difference of absolute expression in isoform level. In 
contrast, DIU assesses the difference of relative expression in isoform level. For example, if 
the expression of two isoforms of one gene are 10 and 20 in control and 50 and 100 in case, 
then there is DIE but no DIU because the relative expression of the first isoform is 1/3 in 
both case and control. Although many methods have been developed to estimate RNA 
isoform expression, only a few methods have been developed to assess DIE or DIU while 
modeling biological variability and accounting for the uncertainty of isoform expression 
estimation. These methods include BitSeq [Glaus et al., 2012], Cuffdiff2 [Trapnell et al., 
2013], and EBseq [Leng et al., 2013]. All three methods are designed for two-group or 
multi-group comparisons with multiple samples per group. BitSeq (Bayesian Inference of 
Transcripts from Sequencing data) adopts a two-stage approach. The first stage is isoform 
expression estimation within each sample using a Bayesian MCMC method. The second 
stage is to assess differential expression of each isoform using the posterior samples from 
the first stage. Cuffdiff2 employs a likelihood-based approach for isoform expression 
estimation and relevant hypothesis testing. For each gene, Cuffdiff2 first estimates 
expectation and covariance of the expression of multiple isoforms, and then uses these 
estimates to assess differential expression of this gene or DIU of its isoforms. For 
differential expression, Cuffdiff2 constructs a test statistic of log fold change, standardized 
by its standard error. Cuffdiff2 offers two tests for DIU: one for all the isoforms sharing a 
transcription starting site (TSS) and one for differential usage of TSSs. The test statistic for 
DIU is the square root of the Jensen-Shannon divergence, divided by its standard error. 
While both BitSeq and Cuffdiff2 first estimate isoform expression and then perform 
hypothesis testing, EB-Seq uses isoform expression estimates from other methods. For two-
group or multi-group comparisons, EBSeq assumes the (rounded) isoform expression 
estimate follows a negative binomial distribution with group-specific mean and 
overdispersion. EBSeq stratifies all isoforms into multiple categories to allow category-
specific mean-variance relations. These isoform categories are constructed based on the 
Sun et al. Page 3













difficulty of isoform expression estimation. For example, genes with one, two, or more 
isoforms may form three categories.
BitSeq, Cuffdiff2, and EBseq all address an important issue for differential isoform 
expression (DIE): to account for the uncertainty inherent in the isoform expression 
estimation process. However, there are two types of commonly encountered tasks that 
cannot be accomplished by these methods: to assess DIE with respect to a continuous 
variable, e.g., age or additive coding of genotype (i.e., 0, 1, 2, for genotype AA, AB, and 
BB), and to assess DIE across two groups with only one sample per group, which is not an 
uncommon situation in real data studies. For example, one may wish to compare isoform 
expression between the paternal and maternal alleles of an individual or between normal and 
cancer tissues of a patient. In such situations, the RNA-seq data allow a valid statistical test, 
although the population for statistical inference is limited to the tested case and control (i.e., 
what happens if we collect more RNA-seq fragments from this case and this control) rather 
than the general case and control populations (i.e., what happens if we collect more samples 
from case or control population). BitSeq and EBseq cannot compare two groups with one 
case and one control. Cuffdiff2 provides an ad-hoc implementation for this problem. 
Specifically, when there is one case and one control, Cuffdiff2 estimates isoform expression 
variance by combining case and control, which implicitly assumes most isoforms are not 
differentially expressed. Therefore it is expected that Cuffdiff2 would yield conservative p-
values and limited power in this situation, which is confirmed in our simulation studies.
In this paper, we develop a statistical method named IsoDOT, which assesses DIE or DIU 
using RNA-seq data and addresses the aforementioned two tasks that cannot be 
accomplished by existing methods. IsoDOT treats all the RNA isoforms of a gene (or a 
transcript cluster of a few overlapping genes) as a unit and tests whether any of these RNA 
isoforms is associated with a covariate of interest. Alternative strategies would be to assess 
differential expression or differential usage of each exon set or each RNA isoform. For 
testing at the exon set level, the number of tests is much larger than gene-level testing, 
which increases the burden on multiple testing correction. In fact, multiple testing correction 
is also more challenging because multiple exon sets of the same gene often have correlated 
expression. For isoform-level testing, the major challenge is to incorporate the uncertainty in 
isoform expression estimation into the testing step. It is possible that two isoforms are very 
similar and thus available data cannot distinguish them. Therefore differential expression 
testing for these two isoforms separately is problematic. By performing testing per transcript 
cluster, IsoDOT bypasses the limitation of exon-set-level or RNA-isoform-level testing. 
After transcript clusters with significant DIE or DIU are identified, one may follow up on 
these transcript clusters to identify differentially expressed exon sets [Anders et al., 2012] or 
isoforms [Glaus et al., 2012, Trapnell et al., 2013, Leng et al., 2013].
Materials and Methods
An overview
We assume that the locations and sizes of all the exons of a gene are known. If needed, one 
can use existing software (e.g., TopHat [Trapnell et al., 2009]) to detect previously unknown 
exons. The inputs of our method are the bam files of all samples. From each bam file, we 
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derive the number of RNA-seq fragments overlapping each exon set (an exon set includes 
one or more adjacent or non-adjacent exons) and the distribution of RNA-seq fragments' 
lengths (Figure 1(a)). IsoDOT estimates RNA isoform expression across all samples, and 
outputs two p-values per gene: one for testing differential isoform expression (DIE) and one 
for testing differential isoform usage (DIU). The DIE test asks whether the absolute 
expression of any isoform of a gene is associated with the covariate of interest. In contrast, 
the DIU test asks, after adjusting for total expression of the corresponding gene, whether the 
relative expression of any isoform of this gene is associated with the covariate of interest.
As part of IsoDOT, we have developed a penalized regression method, named IsoDetector, 
to estimate RNA isoform expression. In contrast to existing methods [Xia et al., 2011, 
Bohnert and Ratsch, 2010, Li et al., 2011b,a], IsoDetector employs penalized negative 
binomial regression with a log penalty. The negative binomial distribution is commonly 
used to model RNA-seq data, and previous studies have shown that it can account for 
variation in RNA-seq fragment counts across biological replicates [Langmead et al., 2010]. 
Many popular methods for differential expression testing, such as DEseq [Anders and 
Huber, 2010] and edgeR [Robinson et al., 2010], adopt such an assumption. More 
specifically, the negative binomial distribution assumption, denoted by N B(μ,φ), implies 
that the RNA-seq fragment count across biological replicates follows a negative binomial 
distribution with mean value μ and variance μ + μ2φ, where φ is an over-dispersion 
parameter. Therefore, the variance of a negative binomial distribution can be arbitrarily 
large for a large value of φ. The Log penalty, which can be interpreted as an iterative 
adaptive Lasso penalty [Tibshirani, 1996, Zou, 2006, Sun et al., 2010], is flexible enough to 
handle a broad class of penalization problems [Chen et al., 2014]. IsoDOT can test DIE/DIU 
against any categorical or continuous covariate at any sample size, with or without known 
isoform annotation. Our simulation and real data analysis demonstrate that IsoDOT 
performs very well with human or mouse RNA-seq data, but it can of course be applied to 
RNA-seq data from any species with a reference genome.
Two exons of a gene may overlap partially. In such situations, we split them into three 
exons: the part unique to the first or the second exon, and the part that belongs to both 
exons. Multiple genes may overlap on one or more exons, and we consider these genes as a 
transcript cluster, though any isoform of this transcript cluster can only be produced from 
one gene.
Isoform estimation in a single sample
We study the isoforms of each transcript cluster separately, and the following discussion 
applies to a specific transcript cluster. Denote the number of exons of a transcript cluster by 
k. Let A be an exon set, i.e., a subset of the k exons. Let yiA be the number of sequence 
fragments that overlap and only overlap with all the exons of A in the i-th sample, where 1 ≤ 
i ≤ n, and n is the sample size. A sequence fragment overlaps with an exon if the “sequenced 
portion” of this fragment overlaps with at least 1 bp of the exon. For example, if a fragment 
is sequenced by a paired-end read where the first end overlaps with exon 1 and 2 and the 
second end overlaps with exon 4, then this fragment is assigned to exon set A = {1,2,4}.
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To illustrate the main feature of our method, we consider a gene (which is a transcript 
cluster itself) with 3 exons and 3 isoforms (Figure 1(b)). Denote its expression at sample i by 
yi = (yi{1}, yi{2}, yi{3}, yi{1,2}, yi{2,3}, yi{1,3}, yi{1,2,3})T. We assume yiA follows a negative 
binomial distribution ψ(μiA,φ) with unknown mean μiA and dispersion parameter φ. Let μi be 
a column vector concatenating the μiA's, then μi = E(yi). We model μi by:
(1)
where βu is proportional to the transcript abundance of the u-th isoform, Xi = (xi1, …, xip), 
and xiu for 1 ≤ u ≤ p represents the effective lengths of all the exon sets for the u-th isoform 
in the i-th sample. Intuitively, effective length is the “usable length” for the data generation 
mechanism, i.e., the number of positions where a randomly selected sequence fragment can 
be sampled. The effective length of an exon set varies across the underlying isoforms. For 
example, isoforms 1 and 3 of the gene shown in Figure 1(b-c) do not include exon 2, and 
thus the effective length of exon set {2} is 0 for isoforms 1 and 3. In contrast, the effective 
length of exon 2 is nonzero for isoform 2, since it includes exon 2. In addition, effective 
length is also a function of the sample-specific RNA-seq fragment length distribution. The 
desired average length of RNA-seq fragments is often chosen during RNA-seq library 
preparation. However, the true fragment length distribution can be estimated from observed 
RNA-seq data. See Supplementary Materials Section A for details. In this example, the 
design matrix includes the effective lengths of all exon sets for isoforms 1, 2, and 3. Next, 
we recast the isoform estimation problem to a negative binomial regression problem with 
fragment counts yi as response and effective lengths Xi as covariates:
(2)
Equation (2) should be understood such that yiA's are independent of each other and yiA 
follows a negative binomial distribution ψ(μiA,φ). The independence assumption is 
reasonable because the fragment counts across exon sets should be independent given 
isoform configurations.
The regression problem presented in equation (2) is challenging because there can be a large 
number of possible isoforms and their effective lengths (e.g., the columns of the design 
matrix Xi) may be linearly dependent or significantly correlated. To address this difficulty, 
we first select a set of candidate isoforms, and then apply a penalized negative binomial 
regression to select the final set of isoforms from these candidate isoforms. The candidate 
isoforms can be selected using observed RNA-seq data (Supplementary Materials Section B) 
or a transcriptome annotation database (e.g., Ensembl [Flicek et al., 2011]).
In our analysis, we skip the exon sets that have zero or negligible effective lengths across all 
the candidate isoforms because these exon sets are not informative for isoform expression 
estimation. For example, the exon set {2,3} or {1,2,3} in the example shown in Figure 1 (c) 
are not included in the analysis. The number of candidate isoforms, denoted by p, can be 
much larger than the number of (informative) exon sets, denoted by m, and there may be 
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high correlations among the effective lengths of the candidate isoforms. Therefore, selecting 
the final set of isoforms from the candidate isoforms is a challenging variable selection 
problem. Lasso penalty has been applied in previous studies. However, the selection 
consistency of Lasso requires an irrepresentability condition on the design matrix [Zou, 
2006, Zhao and Yu, 2006], which posits that there are weak correlations between the 
“important covariates”, which have non-zero effects and the “unimportant covariates”, 
which have zero effects. This irrepresentability condition is often not satisfied for the 
isoform selection problem due to high correlations among candidate isoforms. We employ a 
Log penalty [Mazumder et al., 2011] for this challenging variable selection problem, which 
does not require the irrepresentability condition and can be interpreted as iterative adaptive 
Lasso [Sun et al., 2010, Chen et al., 2014]. The algorithm for fitting this penalized negative 
binomial regression is outlined in Supplementary Materials Section C.
Isoform estimation in multiple samples
To estimate isoform expression in multiple samples, we have to account for read-depth 
difference across samples. Let ti be a read-depth measurement for the i-th sample. For 
example, ti can be the total number of RNA-seq fragments in the i-th sample, or the 75 
percentile of the number of RNA-seq fragments per gene in the i-th sample [Bullard et al., 
2010]. We first consider a case without any covariate associated with isoform expression. To 
account for read-depth variation, we modify equation (1) to
(3)
where γu is proportional to relative expression of the u-th isoform, after normalizing by ti.
Let , , and , where y and μ, are 
vectors of length nm and Z is a matrix of size nm × p. Recall that p is the number of 
candidate isoforms, n is sample size, and m is the total number of exon sets. Then the 
isoform selection problem can be written as a negative binomial regression problem
(4)
After imposing a penalty, we solve this regression problem using the method described in 
Supplementary Materials Section C.
Next we consider isoform estimation given a continuous covariate g = (g1, …, gn)T. We 
assume the expression of an isoform u for sample i, denoted by γiu, is a linear function of 
covariate gi: γiu = au + b̃ugi. This linear model is an appropriate choice when gi represents 
SNP genotype [Sun, 2012], which is the focus of our empirical data analysis. In this linear 
model setup, a complex set of constraints is needed for au and b̃u so that γiu ≥ 0 for any 
value of gi. Therefore we reformulate the problem as follows. Without loss of generality, we 
scale the value of gi to be within the range of [0,1] with the minimum and maximum values 
being exactly 0 and 1, respectively. For example, if gi corresponds to a SNP with additive 
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effect, we can set gi = 0, 0.5, or 1 for genotype AA, AB, or BB. Let bu = b̃u + au, then γiu = 
au + (bu − au)gi = au(1 − gi) + bugi. Under this model, we have
Let a = (a1,…, ap)T and b = (b1,…, bp)T, we have
(5)
By concatenating a and b into a vector: θ = (a1, …, ap,b1, …,bp)T, we can rewrite equation 
(5) as μi = Wiθ, where Wi = [tiXi(1 − gi), tiXigi] is an m × 2p matrix. Let 
, then the isoform expression estimation problem reduces to a 
negative binomial regression problem with non-negative coefficients
(6)
After imposing a penalty, we solve the resulting penalized regression problem by the 
coordinate ascend method described in Supplementary Materials Section C.
Finally we consider the general situation with q covariates, denoted by g1,…, gq, where gv = 
(g1v, …,gnv)T for v = 1, …,q. Without loss of generality, we assume 0 ≤ giv ≤ 1 for 1 ≤ i ≤ n 
and 1 ≤ v ≤ q. Then we model γiu by 
. This is simply a multiple 
linear regression model where each covariate gv has its own effect. Let a = (a1,…, ap)T and 
bv = (b1v,…, bpv)T, then
(7)
By concatenating a, b1, b2, …, bq into a vector: , we rewrite the 
above equation as μi = Wiθ, where  is an m 
× (q + 1)p matrix. Let , then we form an negative binomial regression 
problem
(8)
After imposing a penalty on each θj, we can solve the resulting penalized regression problem 
by the coordinate ascend method described in Supplementary Materials Section C.
When studying multiple samples, it is possible that an exon set is only expressed in a subset 
of samples. Therefore, when examining the fragment counts of this exon set across all 
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samples, there are more 0's than expected by a negative binomial distribution. In such case, 
we introduce a zero-inflated component and employ the zero-inflated negative binomial 
distribution [Rashid et al., 2011] to model RNA-seq fragment count data.
Testing for differential isoform expression (DIE)
We have described the statistical model to estimate RNA isoform expression in multiple 
samples given one or more covariate. Building on this model, we assess differential isoform 
expression with respect to a set of covariates denoted by V using a likelihood ratio test. 
Specifically, the null hypothesis (H0) is that buv = au for u = 1, …,p and v ∊ V and the 
alternative hypothesis (H1) is that buv ≠ au for at least one pair of (u, v), where u = 1, …,p 
and v ∊ V. It is helpful to understand this test by considering two special cases. First, we 
assume there is only one numerical covariate. Under H0, we solve the isoform estimation 
problem by a penalized negative binomial regression with expected value μi = tiXia. Under 
alternative, μi = tiXi[a(1 − gi) + bgi]. Therefore the number of parameters is p under H0 and 
2p under H1. The asymptotic Chi-square distribution with degree of freedom p does not 
apply because the models are estimated, under both H0 and H1, by penalized regression. In 
the second special case, we assume the only variable of interest is a categorical variable with 
d categories. This categorical variable can be coded as d − 1 binary variables, dented by gi1,
…, gi,d−1. The expected values of fragment counts across exon sets under H0 and H1 are μi = 
(d − 1)tiXia and , respectively. 
Therefore the number of parameters under H0 and H1 are p and dp, respectively. Again, the 
asymptotic Chi-square distribution with degree of freedom (d − 1)p does not apply because 
the models are estimated, under both H0 and H1, by penalized regression.
We use likelihood ratio (LR) statistic as our test statistic:
where ℓ0 and ℓ1 are the log likelihoods under null and alternative, respectively. Because of 
penalized estimation, the null distribution of this test statistic no longer follows the standard 
asymptotic distribution. We obtain the null distribution by parametric bootstrap or 
permutation. The parametric bootstrap approach proceeds as follows. (1) Fit the penalized 
negative binomial regression under null. (2) Sample fragment counts based on the fitted null 
model. (3) Using the sampled counts to refit models under null and alternative and calculate 
the LR statistic. (4) Repeat steps (1)-(3) a large number of times as needed [Jiang and 
Salzman, 2012]. (5) Calculate the p-value as the proportion of the bootstrapped LR statistics 
that are larger than  . This parametric bootstrap procedure yields valid p-values regardless 
of the sample size n. However, since the sampling population is all the RNA-seq fragments 
from the studied samples, small p-values only imply a significant difference of the studied 
samples and should not be generalized to other individuals.
If sample size is sufficiently large (e.g., ≥ 5 cases vs. ≥ 5 controls), we can obtain valid 
statistical inference for the corresponding population (instead of studied samples) by 
calculating permutation p-values. Specifically, the null model is fitted without the covariate 
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of interest, and thus its log likelihood l0 remains unchanged across permutations. In each 
permutation, we permute the covariate of interest and refit the alternative model, and then 
calculate the likelihood ratio test statistic. We repeat this process a large number of times to 
obtain a null distribution of the likelihood ratio statistic.
Testing for differential isoform usage (DIU)
All the previous discussion, including RNA isoform expression estimation and differential 
isoform expression testing, focus on absolute expression of RNA isoforms, which is RNA 
isoform expression after correcting for read-depth variation across samples. Another 
measure of RNA isoform expression, which may be more interesting in many situations, is 
the relative expression with respect to the total expression of the corresponding gene or 
transcript cluster. This is because a gene may have higher or lower expression overall, and it 
may also switch the usage of some RNA isoforms. For example, a gene may predominately 
use one isoform in one tissue and switch to another isoform in another tissue. Such relative 
expression of an RNA isoform is referred to the isoform usage. For a transcript cluster of 
interest, we denote the total number of RNA-seq fragments in the i-th sample by ri. Recall 
that in the previous discussions of DIE, ti denotes a read-depth measurement for the i-th 
sample. To assess DIU, we apply the same procedure as assessing DIE, except that we 
replace ti by ri.
Results and Discussions
Simulation for case-control comparison
We simulated ∼1 million 76 + 76 bps paired-end RNA-seq reads for a single case and 
control sample respectively using Flux Simulator (http://flux.sammeth.net/simulator.html) 
and the Ensembl transcriptome annotations (version 67, http://useast.ensembl.org/info/
data/ftp/index.html) for chromosome 1 (chr1) and chromosome 18 (chr18) for the mouse 
genome. We simulated the data such that all genes from chr1 were equivalently expressed 
and all genes from chr18 were differentially expressed, either in terms of total expression or 
isoform usage (Supplementary Figure 2). These simulated RNA-seq reads were mapped to 
the reference genome using Tophat [Trapnell et al., 2009]. Next, we counted the number of 
RNA-seq fragments per exon set. It was important to consider all exon sets rather than just 
exon or exon junctions because many RNA-seq fragments overlap with more than two 
exons. For example, in this simulated dataset, ∼27% of the paired-end reads overlapped 3 or 
more exons (Supplementary Figure 3). In addition, we confirmed that the number of 
sequence fragments per exon set was proportional to the effective length of the exon set 
(Supplementary Figure 4).
The dimension of this problem (i.e., the number of exon sets m versus the number of 
candidate isoforms p) was illustrated in Supplementary Figures 5-6. Given transcriptome 
annotation, p < m for the vast majority of transcript clusters, and without transcriptome 
annotation, we restricted the number of candidate isoforms so that approximately p < 10m. 
In either case, there were strong correlations among the candidate isoforms (Supplementary 
Figures 7-8), therefore necessitating the use of penalized regression in IsoDetector. After 
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applying penalized regression, most transcription clusters included 10 or fewer isoforms, 
with or without transcriptome annotation (Supplementary Figures 9-10).
We compared isoform abundance estimates from IsoDetector and Cufflinks (v2.0.0) 
[Trapnell et al., 2010, 2013] using the case sample. The conclusions from the control sample 
were similar (results not shown). We focused on 1,062 transcript clusters (corresponding to 
5,185 transcripts) that had at least 2 exons with ≥5 sequence fragments overlapping each 
exon. Most of these transcript clusters included 1-2 genes and 1-42 transcripts, and most of 
the 5,185 transcripts harbored 6-500 RNA-seq fragments (Figure 2a). If transcriptome 
annotation was unavailable, the isoforms selected by IsoDetector were more similar to the 
true ones than Cufflinks (Figure 2b). The two methods had similar accuracy in terms of 
transcript abundance estimation, either with (Figure 2c-2d) or without (Figure 2e-2f) 
transcriptome annotation.
We next compared the power of IsoDOT to that of Cuffdiff (v2.0.0) [Trapnell et al., 2013] 
in terms of testing for differential expression or differential isoform usage. Cuffdiff results 
were obtained from three files: gene_exp.diff (differential expression), splicing.diff 
(differential usage of the isoforms sharing a transcription start site (TSS)), and 
promoters.diff (differential usage of TSSs). The majority of the genes in file 
gene_exp.diff have status “OK” and they were used in the following comparison. 
However, no gene has status “OK” in file splicing.diff or promoters.diff. In these 
two files, all the genes with meaningful p-values have status “NOTEST”, indicating that 
Cuffdiff recommends users not to trust these testing results. The reason is as follows. For a 
two group comparison with one case and one control, Cuffdiff combines the case and the 
control to estimate variance of biological replicates, which leads to a very conservative p-
value since this approach implicitly assumes the case and the control have the same 
expected value. Nonetheless, these genes with status “NOTEST” were used in the following 
comparison because they are the only genes that we can use. A gene could have multiple p-
values in splicing.diff. In favor of Cuffdiff for power comparison, we used the smallest 
p-value for each gene. Based on our simulation setup, power was defined as the proportion 
of the genes from chr18 that had significant DIE or DIU. IsoDOT had substantially higher 
power than Cuffdiff (Figure 3), attributed to the correct type I error control of IsoDOT 
(Supplementary Figure 11). The poor performance of Cuffdiff is not simply a calibration 
issue because IsoDOT still performs better than Cuffdiff when we compare two methods 
using ROC curves (Supplementary Figure 12). Instead, the poor performance of Cuffdiff is 
because it tries to estimate variance across biological replicates when there is no biological 
replicate at all. IsoDOT can perform a valid test because it does not try to estimate variance 
of biological replicates. Instead, it tries to estimate the variance due to resampling of RNA-
seq reads. To be fair, Cuffdiff does recommend such test with one case versus one control 
and we include Cuffdiff in our comparison because it is the only method that allows for such 
testing. In conclusion, this simulation illustrated that IsoDOT worked well in this 
challenging situation of comparing one case vs. one control.
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Simulation for isoform usage eQTL
To illustrate the performance of IsoDOT in testing differential isoform usage with respect to 
a continuous covariate, we applied IsoDOT to map isoform usage eQTL (gene expression 
quantitative trait locus) using simulated RNA-seq data and real genotype data. We 
downloaded genotype data from 60 European HapMap samples [Thorisson et al., 2005] and 
selected 949,537 SNPs with minor allele frequency (MAF) > 0.05 for the following analysis. 
We defined transcription clusters based on Ensembl annotation (version 66, http://
useast.ensembl.org/info/data/ftp/index.html), and selected 200 transcript clusters that 
satisfied the following two conditions for our simulation studies. (1) Each transcript cluster 
has > 1 annotated RNA-isoforms, and (2) Each transcript cluster has ≥ 1 SNP in the gene 
body (any intronic or exonic regions) or within 1000bp of the gene body. For each selected 
transcript cluster, we simulated RNA-seq fragment counts across exon sets under null (H0) 
and alternative (H1), respectively. Specifically, for each gene, we randomly selected 50% of 
the isoforms to have zero expression and set the expression of the other 50% of isoforms by 
drawing γu (equation (4)) from a uniform distribution U[0.5, 1].
Next, we used these simulated data to assess differential isoform usage of each transcript 
cluster with respect to each of the nearby SNPs (within 1000bp of the gene body) and kept 
the most significant eQTL per transcript cluster. For each transcript cluster, up to 1000 
permutations were carried out to correct for multiple testing across the multiple nearby 
SNPs. Under H0, the permutation p-values followed a uniform distribution; and under H1, 
the permutation p-values were obviously enriched with small values (Figure 4(a)). In this 
simulation, we had ∼ 80%/40% power to detect local isoform usage eQTL for permutation 
p-value cutoffs 0.05 and 0.005, respectively (Figure 4(b)). Therefore, this simulation 
demonstrates that IsoDOT correctly controls type I error and has power to detect differential 
isoform usage with respect to a continuous covariate.
Haloperdiol treatment effect on mouse transcriptome
Haloperidol is a drug used to treat schizophrenia, acute psychotic states, and delirium. A 
major adverse side effect of chronic haloperidol treatment is tardive dyskinesia (TD). TD 
can be modeled in mice be examining haloperidol-induced vacuous chewing movements 
(VCMs) [Crowley et al., 2012]. We applied IsoDOT to analyze RNA-seq data for mice 
treated with haloperidol vs. placebo with particular interest in identifying genes responding 
to haloperidol treatment and/or responsible for VCM. RNA-seq data were collected from 
whole brains from four mice: two C57BL/6J mice treated with haloperidol or placebo and 
two 129S1Sv/ImJ×PWK/PhJ F1 mice treated with haloperidol or placebo. Each RNA-seq 
fragment was sequenced on both ends by 93 or 100bp, and 20-27 million RNA-seq reads 
were collected for each mouse (Supplementary Table 1). See Supplementary Materials 
Section D for additional details of the experiment.
We first studied differential isoform expression/usage between two C57BL/6J mice. RNA-
seq reads were mapped to the mm9 reference genome using TopHat [Trapnell et al., 2009]. 
At FDR of 5%, IsoDOT identified 86 or 88 genes with differential isoform usage (DIU), 
with or without transcriptome annotation, respectively. For the test of differential isoform 
expression (DIE), also at FDR of 5%, IsoDOT identified 332 or 206 genes with or without 
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transcriptome annotation, respectively. We sought to gain some insight of these four gene 
lists by applying functional category enrichment analysis [Sherman et al., 2009] on the top 
100 genes in each list. Only those DIU genes identified with transcriptome annotation were 
significantly associated with biologically relevant categories such as neuron projection 
(Supplementary Figure 13-16). This implied that DIU, rather than DIE, might be more 
relevant to haloperidol treatment in C57BL/6J mice. The gene lists identified without 
transcriptional annotation did not show functional enrichment, which implied larger sample 
size or higher read-depth were needed to detect DIE or DIU without transcriptome 
annotation. According to Cuffdiff manual, it is not recommended to run Cuffdiff with 
sample size one versus one. However, we still evaluated the performance of Cuffidff in this 
dataset for comparison purpose. Using the results reported by Cuffdiff, no gene has q-value 
smaller than 0.05 (with or without annotation, alternative promoter or alternative splicing), 
and functional category enrichment analysis [Sherman et al., 2009] on the top 100 genes 
reported by Cuffdiff identified no significantly enriched functional category (Supplementary 
Figure 17).
Several DIU genes identified by IsoDOT can be potential targets for follow up studies 
(Supplementary Table 2). For example, Utrn (utrophin, Figure 5) and Dmd (dystrophin) are 
both involved in neuron projection and could be candidates underlying the VCM side effect. 
Grin2b (glutamate receptor, ionotropic, NMDA2B, Supplementary Figure 18) or its human 
ortholog is involved in Alzheimer's disease, Huntington's disease, and amyotrophic lateral 
sclerosis (ALS), which are potentially relevant to the VCM side effect of haloperidol 
treatment. In addition, our previous studies had prioritized several other glutamate receptors 
such as Grin1 and Grin2a as candidates that response to haloperidol treatment using 
independent data and methods [Crowley et al., 2012].
Similar studies were conducted for the two F1 mice of 129S1Sv/ImJ×PWK/PhJ. To better 
map RNA-seq reads, we first built two pseudogenomes for 129S1Sv/ImJ and PWK/PhJ by 
incorporating Sanger SNPs and indels [Keane et al., 2011] into the reference genome and 
mapped RNA-seq reads to the two pseudogenomes separately. Next, alignments were 
remapped back to the reference coordinate system and the observed genetic variants were 
annotated for each RNA-seq fragment. IsoDOT identified much less DIU or DIE genes in 
these two F1 mice than in the two C57BL/6J mice. At FDR 0.2, no DIU genes were 
identified and 85 DIE gene were identified. Six of these 85 genes were involved in actin-
binding, though this functional category was not significantly overrepresented.
The greater level of DIE and DIU in C57BL/6J than 129S1Sv/ImJ×PWK/PhJ following 
chronic haloperidol treatment was consistent with behavioral phenotype data which showed 
that C57BL6/J mice had greater susceptibility to haloperidol-induced VCM (Supplementary 
Figure 19) [Crowley et al., 2012]. Therefore, some of the C57BL/6J transcriptional changes 
detailed in this study might contribute to the development of haloperidol-induced VCM.
Allele-specific differential isoform usage
About 37.2% of the RNA-seq fragments from the two 129S1Sv/ImJ×PWK/PhJ F1 mice 
were only mapped to the paternal or maternal allele or were mapped to one allele with fewer 
mismatches, and hence they were allele-specific RNA-seq fragments. There was no genome-
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wide bias, i.e., ∼50% of the allele-specific RNA-seq fragments were mapped to each 
parental strain (Supplementary Table 1). Using these allele-specific RNA-seq fragments, we 
applied IsoDOT to assess differential isoform usage between maternal and paternal alleles. 
At a liberal FDR cutoff 0.2, no DIU gene was identified, and 19 or 30 DIE genes were 
identified from the haloperidol/placebo treated F1 mice, respectively. The genes with 
significant differential isoform usage in the haloperidol treated mice, but not the placebo 
treated mice might indicate genetic×treatment interactions. Supplementary Table 3 listed 23 
such genes with DIU p-values < 0.01 in the haloperidol treated mice, and DIU p-values > 
0.1 in the placebo treated mice. Among them, Synpo and Snap25 are associated with neuron 
functions. Snap25 is known to be associated with schizophrenia and/or haloperidol treatment 
at DNA [Müller et al., 2005], RNA [Sommer et al., 2010], and protein levels [Thompson et 
al., 1998, Honer et al., 2002]. To the best of our knowledge, this is the first report that the 
differential isoform usage of Snap25 is associated with genetic×haloperidol treatment 
interaction.
Software and data availability
An R package of IsoDOT is available at http://www.bios.unc.edu/∼weisun/software/
isoform.htm. Testing differential isoform expression/usage is computationally intensive. 
Using IsoDOT with up to 1,000 parametric bootstraps, it will take on average 1-3 minutes to 
test differential isoform usage for a gene on a single processor. Parallel computation is 
needed and straightforward for genome-wide study. We are also actively working on 
implementing our method using Graphics Processing Unit (GPU) using the massively 
parallel algorithm described in Supplementary Materials Section E. Simulated RNA-seq data 
can be downloaded from http://www.bios.unc.edu/∼weisun/software/isoform_files/. The 
RNA-seq data of mouse haloperidol treatment experiment are available from NCBI GEO 
(GSExxx).
Discussion
We have developed a new statistical method named IsoDOT to assess differential isoform 
expression or usage from RNA-seq data with respect to categorical or continuous covariates. 
The resampling based approach is the basis of our hypothesis testing method. Two 
components of our method, the negative binomial distribution assumption and the Log 
penalty for penalized estimation are important for the success of this resampling based 
approach. First, the negative binomial distribution is a well-accepted choice for modeling 
RNA-seq fragment data across biological replicates. For the completeness of our paper, we 
also demonstrate that the negative binomial distribution provides a good fit of RNA-seq 
fragment counts, while the Poisson distribution assumption leads to a severe underestimate 
of variance (Supplementary Figure 20). Replacing the Log penalty with the Lasso penalty in 
IsoDOT leads to inaccurate type I error control and/or reduced power (Supplementary 
Figure 21). The limitation of Lasso is especially apparent when we do not use isoform 
annotation, where the number of candidate isoforms is much larger than sample size. This is 
consistent with previous findings that Lasso tends to select more false positives and has 
larger bias in effect estimates than the Log penalty [Chen et al., 2014].
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Some biases should be accounted for to obtain better estimates of RNA isoform abundance. 
For example, the RNA-seq reads may not be uniformly distributed along the transcript, and 
DNA sequence features such as GC content may affect the abundance of RNA-seq reads. 
Such biases, if they exist, affect both the likelihoods under the null and alternative 
hypotheses and do not alter our Type I error rate. Furthermore, it may have limited impact 
on power because we calculate p-values through resampling approaches. For example, if the 
last exon of a gene tends to have a larger number of RNA-seq reads, our method may 
overestimate the expression of the isoform harboring the last exon. However, such over-
estimation occurs under both the null and alternative hypotheses and, therefore, does not 
lead to inflated or deflated type I error. Systematically accounting for such biases are among 
our future plans to improve IsoDOT?s performance.
A major strength of IsoDOT is that it allows the assessment of differential isoform usage 
between one case and one control sample. This is especially important for paired samples, 
e.g., maternal and paternal alleles of one individual. When there are multiple paired samples, 
we can combine the p-values of multiple pairs using meta-analysis via Fisher's method or 
Stouffer's Z-score [Hunter et al., 1982]. In the preliminary study reported in this paper, we 
have identified several interesting genes (Utrn, Dmd, Grin2b, Snap25) whose isoform usage 
may respond to haloperidol treatment and are perhaps related to its side effects. In the near 
future, we plan to extend this study to include a much larger number of mice with diverse 
genetic backgrounds including mice from the Collaborative Cross [Churchill et al., 2004, 
Consortium, 2012].
Recently developed sequencing techniques can now deliver longer reads, including 2 × 250 
bp reads from Illumina's MiSeq or 400 bp reads from Ion Torrent. Our methods can handle 
these longer sequencing reads without any difficulty. In fact, when the RNA-seq reads are 
long enough, transcriptome reconstruction becomes much easier. However, until all the 
isoforms of a transcript cluster can be unambiguously reconstructed and all the RNA-seq 
fragments can be assigned to an isoform with (almost) 100% certainty, testing differential 
isoform expression/usage remains a challenging problem where methods and software such 
as IsoDOT are needed. Another recently developed RNA-seq technique is to deliver 
“stranded” sequences so that RNA-seq from sense and antisense strands are separated. For 
the analysis of such stranded RNA-seq data, the only step in the IsoDOT pipeline that needs 
to be modified is to count the RNA-seq fragments for sense and anti-sense strands 
separately.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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(a) IsoDOT work flow. The dash line indicates that known isoform annotation (i.e., 
transcriptome annotation) is optional, (b) A gene with 3 exons and 3 possible isoforms. (c) A 
matrix of input data. Each row corresponding to an exon set. The column “Count” is the 
number of RNA-seq fragments at each exon set, and the columns “isoform k” for k = 1,2,3 
give the effective lengths of each exon set within each isoform, and specifically, ηA,k is the 
effective length of exon set A for the k-th isoform. NB(μ,φ) indicates a negative binomial 
distribution with mean μ, and dispersion parameter φ.
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(a) A summary of the RNA-seq data and annotation of the simulated case sample. (d) 
Density curves of the distance between each de novo transcript and its closest transcript 
from transcriptome annotation. The distance is defined as the ratio of the number of 
unmatched base pairs over the total number of base pairs covered by either isoform. A base 
pair is “matched” if it corresponds to an exon or intron location for both isoforms. (c-d) 
Comparison of true transcript abundance vs. estimates from IsoDetector or Cufflinks when 
we use known isoform annotation. Both X and Y-axes are in log10 scale. “n” is the number 
of transcripts with status “OK” for either IsoDetector or Cufflinks. (e-f) Comparison of true 
transcript abundance vs. estimates from IsoDetector or Cufflinks when we do not use any 
isoform annotation.
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Compare the power of IsoDOT and Cuffdiff for detesting genes with differential isoform 
usage (a-b) or differential isoform expression (c-d), while transcriptome annotation is known 
(a,c) or not (b,d).
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Simulation results for testing isoform-usage eQTL on 200 transcription clusters. (a) The qq-
plot for p-values distributions against expected uniform distribution. (b) Power (H1) or type 
I error (H0) for different p-value cutoffs.
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Differential isoform usage of gene Utrn between a mouse with haloperidol treatment and a 
mouse with placebo. The top panel shows the read-depth of RNA-seq reads in two 
conditions. Two annotated isoforms and all the exons are illustrated in middle panel. The 
expression of each isoform under two conditions are shown in the bottom panel.
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